Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Plasma Cell Disorders

Bortezomib improves outcome after SCT in multiple myeloma patients with end-stage renal failure

Bone Marrow Transplantation volume 49, pages 1371–1375 (2014)Cite this article

Subjects

Abstract

Patients with multiple myeloma and dialysis-dependent renal failure have dismal outcomes. In this retrospective analysis of a case series, we evaluated 27 consecutive patients, all of whom required haemodialysis at the time of first-line induction therapy with either bortezomib or a standard regimen followed by high-dose chemotherapy and auto-SCT. The overall response rate was significantly better after bortezomib-based induction before auto-SCT (83% vs 36%, P=0.02) and at day +100 post auto-SCT (100% vs 58%, P=0.01). Bortezomib also prolonged EFS and furthermore, a trend towards a shorter time on haemodialysis was observed in the bortezomib group at a median of 6.1 months (0.2–68.2 months) vs 17.1 months (0.7–94.3 months, P=0.38) in patients who had received vincristine, adriamycin, dexamethasone or vincristine, adriamycin, dexamethasone-like induction regimens. These data demonstrate the superior efficacy of bortezomib-based induction therapy in transplant-eligible patients with end-stage renal failure.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002—Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2005; 23: 9219–9226.

    Article  Google Scholar 

  2. Blade J, Fernandez-Llama P, Bosch F, Montoliu J, Lens XM, Montoto S et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998; 158: 1889–1893.

    Article  CAS  Google Scholar 

  3. Knudsen LM, Hjorth M, Hippe E . Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 2000; 65: 175–181.

    Article  CAS  Google Scholar 

  4. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A et al. Review of 1027 Patients With Newly Diagnosed Multiple Myeloma. Mayo Clinic Proc 2003; 78: 21–33.

    Article  Google Scholar 

  5. Knudsen LM, Nielsen B, Gimsing P, Geisler C . Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur J Haematol 2005; 75: 27–33.

    Article  Google Scholar 

  6. Torra R, Blade J, Cases A, Lopez-Pedret J, Montserrat E, Rozman C et al. Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol 1995; 91: 854–859.

    Article  CAS  Google Scholar 

  7. Raab MS, Breitkreutz I, Hundemer M, Benner A, Klaus J, Hegenbart U et al. The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure. Haematologica 2006; 91: 1555–1558.

    CAS  Google Scholar 

  8. Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 114: 822–829.

    Article  CAS  Google Scholar 

  9. Chanan-Khan AA, Kaufman JL, Mehta J, Richardson PG, Miller KC, Lonial S et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 2007; 109: 2604–2606.

    Article  CAS  Google Scholar 

  10. Dimopoulos MA, Christoulas D, Roussou M, Kastritis E, Migkou M, Gavriatopoulou M et al. Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment. Eur J Haematol 2010; 85: 1–5.

    Article  CAS  Google Scholar 

  11. Ludwig H, Drach J, Graf H, Lang A, Meran JG . Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica 2007; 92: 1411–1414.

    Article  CAS  Google Scholar 

  12. Morabito F, Gentile M, Ciolli S, Petrucci MT, Galimberti S, Mele G et al. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. Eur J Haematol 2010; 84: 223–228.

    Article  CAS  Google Scholar 

  13. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467–1473.

    Article  CAS  Google Scholar 

  14. Tsakiris DJ, Stel VS, Finne P, Fraser E, Heaf J, de Meester J et al. Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study. Nephrol Dial Transplant 2010; 25: 1200–1206.

    Article  Google Scholar 

  15. Parikh GC, Amjad AI, Saliba RM, Kazmi SM, Khan ZU, Lahoti A et al. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant 2009; 15: 812–816.

    Article  Google Scholar 

  16. Glavey SV, Gertz MA, Dispenzieri A, Kumar S, Buadi F, Lacy M et al. Long-term outcome of patients with mutiple myeloma-related advanced renal failure following auto-SCT. Bone Marrow Transplant 2013; 48: 1543–1547.

    Article  CAS  Google Scholar 

  17. Dimopoulos MA, Roussou M, Gkotzamanidou M, Nikitas N, Psimenou E, Mparmparoussi D et al. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia 2013; 27: 423–429.

    Article  CAS  Google Scholar 

  18. Haynes RJ, Read S, Collins GP, Darby SC, Winearls CG . Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20-year experience from a single centre. Nephrol Dial Transplant 2010; 25: 419–426.

    Article  Google Scholar 

  19. Sinisalo M, Silvennoinen R, Wirta O . High cut-off hemodialysis and bortezomib-based therapy to rescue kidneys in myeloma-dependent cast nephropathy. Am J Hematol 2012; 87: 640.

    Article  Google Scholar 

  20. Hutchison CA, Bradwell AR, Cook M, Basnayake K, Basu S, Harding S et al. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol 2009; 4: 745–754.

    Article  CAS  Google Scholar 

  21. Leung N, Gertz MA, Zeldenrust SR, Rajkumar SV, Dispenzieri A, Fervenza FC et al. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int 2008; 73: 1282–1288.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank the Dietmar-Hopp Foundation and the German Cancer Aid for financial support. This work was also supported by the medical faculty of science of the University of Heidelberg, Germany.

Author information

Authors and Affiliations

  1. Max-Eder-Group ‘Experimental Therapies for Hematologic Malignancies’, Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany

    I Breitkreutz & M S Raab

  2. Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg, Germany

    I Breitkreutz, D Jäger & H Goldschmidt

  3. Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany

    C Heiss, A Perne, G Egerer, A D Ho, K Neben, H Goldschmidt & M S Raab

  4. Division of Nephrology, Heidelberg University Hospital, Heidelberg, Germany

    J Beimler & M Zeier

Authors
  1. I Breitkreutz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C Heiss
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Perne
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J Beimler
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D Jäger
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G Egerer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A D Ho
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. K Neben
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M Zeier
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. H Goldschmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. M S Raab
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to I Breitkreutz or M S Raab.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Breitkreutz, I., Heiss, C., Perne, A. et al. Bortezomib improves outcome after SCT in multiple myeloma patients with end-stage renal failure. Bone Marrow Transplant 49, 1371–1375 (2014). https://doi.org/10.1038/bmt.2014.165

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2014.165

This article is cited by

Search

Advanced search

Quick links